Are Your Design Controls Ready for QMSR Scrutiny? 5 Common Design Control Gaps the FDA Will Focus On
The FDA’s Quality Management System Regulation (QMSR), effective February 2, 2026, represents far more than a routine regulatory update. It fundamentally changes how the FDA will evaluate design controls during inspections and how prepared medical device organizations must be to defend them.
As 21 CFR Part 820 aligns withISO 13485,FDA inspections are moving beyond confirmation that documents exist. Inspectors will now evaluate whether design controls operate as a connected, traceable, and defensible system, one that integrates risk management, verification and validation, change control, and post market feedback across the entire product lifecycle.
For many device organizations, this shift exposes uncomfortable realities. Systems that passed prior inspections may not withstand QMSR-level scrutiny, not because teams lack effort or intent, but because their design controls were built around documents rather than systems.
Below are five design control gaps the FDA is increasingly likely to focus on under QMSR and why many medical device companies may not be as prepared as they believe.
1. Technical Documentation That Doesn’t Function as a System:
Under QMSR, the FDA aligns more closely with ISO 13485’s concept of integrated technical documentation, often referred to as the Medical Device File. The traditional treatment of the Design History File (DHF) and Device Master Record (DMR) as separate, standalone collections of documents is no longer sufficient.
Inspectors will not simply verify that required files exist. They will evaluate whether technical documentation:
Under QMSR, fragmentation becomes a critical weakness. FDA inspectors will expect teams to explain their product using one coherent body of technical data, not by navigating disconnected documents, spreadsheets, and systems.
When technical documentation does not function as an integrated system, the FDA is likely to interpret this as evidence that design controls and risk are not truly under control, regardless of how complete individual documents appear.
2. Weak Traceability Between Design Controls and Risk Management:
Traceability has always been required. Under QMSR, the standard for traceability rises significantly.
FDA inspectors will increasingly ask questions such as:
Manual traceability matrices and spreadsheet-based approaches often collapse under real-world changes. Under QMSR, the FDA is not interested in traceability that can be reconstructed for an audit. It expects traceability to be continuous, reliable, and demonstrable at any point in time.
When traceability breaks during change, inspections expose gaps that teams often did not realize existed.
3. Static Risk Management Files:
Under QMSR, risk management must function as a living process, aligned with ISO 14971 expectations and integrated across the product lifecycle.
The FDA is likely to focus on whether:
Risk files that are updated only at major milestones or worse, only in preparation for inspections signal that risk is being documented, not actively managed.
Under QMSR, static risk management is no longer defensible.
4. Poor Change Impact Analysis Across Design Controls:
Design changes are where design control systems are most vulnerable and where FDA inspections often uncover systemic weaknesses.
Under QMSR, inspectors will evaluate how organizations assess and manage change, including:
Document-centric change processes frequently miss downstream impacts, creating traceability gaps that surface late during inspections, production, or scale-up when remediation is most disruptive and costly.
5. Design Decisions Locked Inside Documents:
Under QMSR, the FDA is not only evaluating what decisions were made, but why they were made.
When design rationale lives in informal discussions, emails, or disconnected documents:
QMSR places increased emphasis on preserving design intent across the entire product lifecycle, not merely recording final decisions in approved artifacts.
When rationale is not preserved in a structured, traceable way, organizations struggle to defend decisions years later, especially under inspection pressure.
Why These QMSR Design Control Gaps Share a Common Root Cause:
Each of these gap’s points to the same underlying issue: design control systems built on disconnected documents rather than structured, traceable data.
Under QMSR, the FDA is evaluating whether design controls operate as an integrated system capable of withstanding change, inspection, and real world complexity.
Organizations that discover these gaps during an FDA inspection are likely to face:
How to Assess Your QMSR Design Control Readiness:
QMSR enforcement will not overlook organizations that assume their current design controls are “close enough.”
If you are uncertain how your design control system will perform under QMSR-level scrutiny, it is critical to assess gaps now before the FDA does.
A structured readiness assessment can help identify where systems break down, where risk is not fully controlled, and where technical documentation no longer tells a coherent story.
We hope this information assists your Quality and Development teams. If you would like to discuss how QMSR may impact your development programs or portfolio, please reach out to connect with MIDI for a focused discussion on what readiness looks like in practice.
We do not share your information with third parties
